Features
Anti-VEGF Therapy for Retinopathy of Prematurity
Intravitreal agents that inhibit vascular endothelial growth factor are increasingly used to treat pediatric retinal disease.
By Vernon S. Volante, BS, Lauren C. Kiryakoza, MD, Hong-Uyen Hua, MD
The Evolution of Clinical Trial Endpoints for Wet AMD
As new treatments are introduced, the endpoints that drive regulatory approvals are constantly changing.
By Ruwan Amila Silva, MD, MPhil
Web Exclusives
Results of Recent Trials of Duravyu for Wet AMD
Phase 2 trials showed promise and phase 3 trials will begin shortly.
By Carl D. Regillo, MD, FACS
A Plan for Biosimilar Integration
Incorporating biosimilars into a retina practice requires thoughtful planning, diligent oversight, and an adaptable mindset.
By Derek Burns, PharmD, MBA, BCPS, BCSCP, Lisa Lasita, PharmD, MBA
Departments
Upfront: Time for Fewer, But Stronger, Retina Societies
By Peter K. Kaiser, MD
Uveitis Corner: Conserved Chemokine Gradients in Uveitis
A recent study suggests that therapeutically targeting ocular macrophages and the chemokines CCL2 and/or CXCL10 may provide an effective strategy for treating uveitis.
By Lynn Hassman, MD, PhD, Joseph Lin, BS, Kathryn L. Pepple, MD, PhD
Clinical Trial Download: The Potential of Optogenetic Therapy
Nanoscope Therapeutics’s MCO-010 offers an interesting mechanism of action for restoring vision in patients with retinitis pigmentosa and Stargardt disease.
By Yasha Modi, MD , Allen C. Ho, MD, Sulagna Bhattacharya, MBA
Participating in Clinical Trials as a Retina Specialist
A Conversation with David A. Eichenbaum, MD, FASRS
By David A. Eichenbaum, MD
Coding: Separate Procedures and NCCI Bundles
In certain cases, procedures that are usually bundled under NCCI edits can be reimbursed when performed as a distinct service.
By Brandy H. Sperry, COMT, COE, CPC, CPMA
Clinical Trial Update October 2024
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
News
Transformative Strategies in Ocular Oncology Presented at AAO 2024
Evolving approaches to treatment, and advancements in identifying and treating ocular melanomas, have greatly improved patient survival rates and quality of life.
By Jim Gallagher, senior managing editor
Faricimab Effective in Underrepresented DME Patients
Data from the ELEVATUM trial, presented at AAO, indicates that Hispanic and Black patients with diabetic macular edema responded well to treatment with faricimab.
By Jim Gallagher, senior managing editor
Pegcetacoplan an Effective Treatment for Subfoveal GA
Three-year data from the GALE open-label extension study, presented at AAO, demonstrated an anatomical and visual function benefit of continuous pegcetacoplan treatment for patients with subfoveal geographic atrophy.
By Jim Gallagher, senior managing editor
Scleral Buckling: Let There Be Light
The chandelier scleral buckle procedure, using radial or segmental sponge explants, offers better visualization, reducing complications and improving outcomes.
By Jim Gallagher, senior managing editor
An AAO Conversation With Steve Charles
The legendary surgeon and innovator delivered the 17th Charles Schepens Lecture during Retina Subspecialty Day on Friday morning. He spoke with Retinal Physician about this honor.
By Jim Gallagher, senior managing editor
Data Presented at AAO Support Utility of Home OCT
Data from 2 pivotal trials showed that the Scanly Home OCT device offers accurate, reliable monitoring for nAMD patients between office visits.
By Jim Gallagher, senior managing editor
Ocular Insert Shows Potential as MacTel Treatment
Pooled data from 3 clinical trials, presented during the AAO meeting in Chicago, indicates revakinagene taroretcel prevents deterioration of visual function.
By Jim Gallagher, senior managing editor
Fellow Eye Dosing of Gene Therapy Found Safe, Effective
First-time results of a bilateral dosing study of subretinal ABBV-RGX-314 for nAMD were presented during Retinal Subspecialty Day at AAO.
By Jim Gallagher, senior managing editor
Epiretinal Membrane Tips From Yasha Modi, MD, at AAO
Yasha Modi, MD, discusses the decision-making process for surgical treatment of epiretinal membrane during Saturday's Retina Subspecialty Day at the 2024 American Academy of Ophthalmology meeting in Chicago.
By Yasha Modi, MD
Eylea HD Data Discussion With Drs. Kaiser and Do at AAO
Peter K. Kaiser, MD, and Diana Do, MD, discuss 3-year data from the PHOTON trial for diabetic macular edema at the 2024 American Academy of Ophthalmology meeting.
By Peter K. Kaiser, MD, Diana V. Do, MD
Paul Hahn, MD, PhD, Discusses Physician Reimbursement at AAO
During Retina Subspecialty Day at AAO 2024, Paul Hahn, MD, PhD, discussed recent studies that examined the financial impact of step therapy and inflation on retinal physician reimbursement. The studies were performed by the Health Economics Committee of the American Society of Retina Specialists.
By Paul Hahn, MD, PhD
Gene Therapy Discussion With Drs. Kaiser and Do at AAO
Peter K. Kaiser, MD, and Diana V. Do, MD, discuss first-time results of a bilateral dosing study of subretinal ABBV-RGX-314 for wet AMD.
By Peter K. Kaiser, MD, Diana V. Do, MD
Observations on the Schepens Lecture
Yasha Modi, MD, discusses the 17th Charles L. Schepens Lecture given by legendary innovator and surgeon Dr. Steve Charles during Retina Subspecialty Day at AAO 2024.
By Yasha Modi, MD
Gildeuretinol Demonstrates Benefit in Low-luminance Visual Function
Data from the SAGA study, presented at AAO, showed patients with geographic atrophy demonstrated a trend toward functional benefit in BCVA at month 24.
By Jim Gallagher, senior managing editor
Regeneron Leaders Recognized for Innovation at Eyecelerator 2024
Drs. Schleifer and Yancopoulos received the Eyecelerator Innovation Award and discussed the long and winding road to success.
By Jim Gallagher, senior managing editor
Supported Content
Optos Ultra-Widefield Image of the Month
UWF-RGB Reveals Bone Spicules, Pallorous Halo & Sclerotic Vessels
By Liliya Sutherland, DO
My Approach to Patient Education With Avacincaptad Pegol Treatment
Engaging patients and setting expectations for future visits helps to build trust and encourages compliance with the treatment protocol.
By Ketan G. Laud, MD
First Top-Line Data from ELEVATUM on Faricimab Treatment in Underrepresented Minority Populations
"This data emphasizes that if we can get these patients onto a more effective agent—such as faricimab—earlier in their treatment course, we can get good results."
By Jeremiah Brown Jr., MS, MD , Michael A. Singer, MD
My Patient-Focused Approach to GA Treatment with Anti-Complement Injections
How do we provide hope for a disease process that can be so unrelenting?
By Daniel K. Bennett, MD